AFT Pharmaceuticals Limited develops, licenses, distributes, and sells pharmaceutical products in New Zealand, Australia, Southeast Asia, and internationally.
Price History & Performance
|Historical stock prices|
|Current Share Price||NZ$4.10|
|52 Week High||NZ$4.00|
|52 Week Low||NZ$5.65|
|1 Month Change||-1.44%|
|3 Month Change||-8.89%|
|1 Year Change||-16.67%|
|3 Year Change||81.42%|
|5 Year Change||33.55%|
|Change since IPO||32.26%|
Recent News & Updates
We Discuss Whether AFT Pharmaceuticals Limited's (NZSE:AFT) CEO Is Due For A Pay Rise
Shareholders will be pleased by the impressive results for AFT Pharmaceuticals Limited ( NZSE:AFT ) recently and CEO...
With AFT Pharmaceuticals Limited (NZSE:AFT) It Looks Like You'll Get What You Pay For
When close to half the companies in New Zealand have price-to-earnings ratios (or "P/E's") below 21x, you may consider...
|AFT||NZ Pharmaceuticals||NZ Market|
Return vs Industry: AFT underperformed the NZ Pharmaceuticals industry which returned 0.7% over the past year.
Return vs Market: AFT underperformed the NZ Market which returned 2.1% over the past year.
Stable Share Price: AFT is less volatile than 75% of NZ stocks over the past 3 months, typically moving +/- 3% a week.
Volatility Over Time: AFT's weekly volatility (3%) has been stable over the past year.
About the Company
AFT Pharmaceuticals Limited develops, licenses, distributes, and sells pharmaceutical products in New Zealand, Australia, Southeast Asia, and internationally. The company offers products for use in the areas of allergy, cold and flu, digestive health, eye care, first aid, nail and oral care, pain management, skin care, and other products, as well as supplements. The company was incorporated in 1997 and is headquartered in Auckland, New Zealand.
AFT Pharmaceuticals Fundamentals Summary
|AFT fundamental statistics|
Is AFT overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|AFT income statement (TTM)|
|Cost of Revenue||NZ$64.36m|
Last Reported Earnings
Mar 31, 2021
Next Earnings Date
Nov 17, 2021
|Earnings per share (EPS)||0.073|
|Net Profit Margin||6.71%|
How did AFT perform over the long term?See historical performance and comparison
Is AFT Pharmaceuticals undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: AFT (NZ$4.1) is trading below our estimate of fair value (NZ$6.37)
Significantly Below Fair Value: AFT is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: AFT is poor value based on its PE Ratio (56.5x) compared to the Oceanic Pharmaceuticals industry average (44.9x).
PE vs Market: AFT is poor value based on its PE Ratio (56.5x) compared to the NZ market (22.2x).
Price to Earnings Growth Ratio
PEG Ratio: AFT is poor value based on its PEG Ratio (1.6x)
Price to Book Ratio
PB vs Industry: AFT is overvalued based on its PB Ratio (11.7x) compared to the XO Pharmaceuticals industry average (3.8x).
How is AFT Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: AFT's forecast earnings growth (34.4% per year) is above the savings rate (2.1%).
Earnings vs Market: AFT's earnings (34.4% per year) are forecast to grow faster than the NZ market (9.2% per year).
High Growth Earnings: earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: AFT's revenue (13.9% per year) is forecast to grow faster than the NZ market (5.3% per year).
High Growth Revenue: AFT's revenue (13.9% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: AFT's Return on Equity is forecast to be high in 3 years time (27.4%)
How has AFT Pharmaceuticals performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: AFT has a high level of non-cash earnings.
Growing Profit Margin: AFT's current net profit margins (6.7%) are lower than last year (11.1%).
Past Earnings Growth Analysis
Earnings Trend: AFT has become profitable over the past 5 years, growing earnings by 57.5% per year.
Accelerating Growth: AFT's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: AFT had negative earnings growth (-35.1%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (17.1%).
Return on Equity
High ROE: Whilst AFT's Return on Equity (21.27%) is high, this metric is skewed due to their high level of debt.
How is AFT Pharmaceuticals's financial position?
Financial Position Analysis
Short Term Liabilities: AFT's short term assets (NZ$67.9M) exceed its short term liabilities (NZ$32.1M).
Long Term Liabilities: AFT's short term assets (NZ$67.9M) exceed its long term liabilities (NZ$36.4M).
Debt to Equity History and Analysis
Debt Level: AFT's debt to equity ratio (104.8%) is considered high.
Reducing Debt: AFT's debt to equity ratio has increased from 82.3% to 104.8% over the past 5 years.
Debt Coverage: AFT's debt is not well covered by operating cash flow (2%).
Interest Coverage: AFT's interest payments on its debt are well covered by EBIT (3.1x coverage).
What is AFT Pharmaceuticals's current dividend yield, its reliability and sustainability?
Forecast Dividend Yield
Dividend Yield vs Market
Notable Dividend: Unable to evaluate AFT's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate AFT's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if AFT's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if AFT's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of AFT's dividend in 3 years as they are not forecast to pay a notable one for the NZ market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Dr. Hartley Atkinson, M.Pharm (Dist), PhD, founded AFT Pharmaceuticals Limited in 1997, has been its Chief Executive Officer since September 04, 1997 and also serves as its Managing Director. Before establ...
CEO Compensation Analysis
Compensation vs Market: Hartley's total compensation ($USD500.78K) is about average for companies of similar size in the NZ market ($USD502.43K).
Compensation vs Earnings: Hartley's compensation has been consistent with company performance over the past year.
Experienced Management: AFT's management team is seasoned and experienced (9.1 years average tenure).
Experienced Board: AFT's board of directors are considered experienced (7.7 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
AFT Pharmaceuticals Limited's employee growth, exchange listings and data sources
- Name: AFT Pharmaceuticals Limited
- Ticker: AFT
- Exchange: NZSE
- Founded: 1997
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: NZ$429.224m
- Shares outstanding: 104.69m
- Website: https://www.aftpharm.com
Number of Employees
- AFT Pharmaceuticals Limited
- 129 Hurstmere Road
- Level 1
- New Zealand
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/10/24 06:00|
|End of Day Share Price||2021/10/22 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.